Cirrhosis
-
Upload
joaquin-masoud-castano-shafiee -
Category
Documents
-
view
10 -
download
0
description
Transcript of Cirrhosis
-
DR. JOAQUIN MASOUD C. SHAFIEE
-
This report has been compiled from various sources on the internet.
I would like to thank the authors of the reports which I might taken the slides from .
This presentation is made to aid the students in 2nd year dentistry course and I hope it will benefit them.
CIRRHOSIS
-
CIRRHOSIS
Cirrhosis is a pathologically defined entity that is associated with a spectrum of characteristic clininical manifestation
1-Irreversible chronic injury of the hepatic parenchyma
2-Extensive fibrosis
3-formation of regenerative nodules
-
Normal liver
-
Cirrhosis of the liver is the third leading cause of death in people between the ages of 25 and 65 years, exceeded only by cardiovascular disease and cancer.
-
The cost of cirrhosis in terms of human suffering, financial burden, and loss of productive life is devastating.
-
PATIENTS WITH CIRRHOSIS MAY PRESENT IN A VARIETY OF WAYS.
Variceal bleeding
New onset of ascites
Hepatomegaly and/or
splenomegaly
-
PATIENTS WITH CIRRHOSIS MAY PRESENT IN A VARIETY OF WAYS.
Incidental Discovery Of Abnormal Laboratory Tests
Serum Aminotransferases,
Hypoalbuminemia,
Prolonged Prothrombin Time,
Hrombocytopenia)
-
PATIENTS WITH CIRRHOSIS MAY PRESENT IN A VARIETY OF WAYS.
Detection of the peripheral stigmata ofchronic liver disease such as
Jaundice, Dupuytren's contracture, Manifestations related to hyperestrogenemia such as oSpider angiomata,
oPalmar erythema,
oGynecomastia, and testicular atrophy which may also be related to low testosterone concentrations
-
PATIENTS WITH CIRRHOSIS MAY PRESENT IN A
VARIETY OF WAYS.
hepatic encephalopathy or one or more complications or systemic manifestations of hepatocellular carcinoma
Some patients never come to clinical attention. In older reviews, cirrhosis was diagnosed at autopsy in up to 30 to 40 percent of patients
-
CIRRHOSIS REPRESENTS THE TERMINAL STAGE OF A NUMBER OF CHRONIC LIVER DISEASES INCLUDING THOSE CAUSED BY
excessive ethanol consumption
Viral hepatitis
Drugs and toxins,
Vascular
Autoimmune
Metabolic disorders
Cryptogenic.
In some cases, no cause can be determined and the cirrhosis is
-
Early cirrhosis may be asymptomatic and undetectable except by biopsy.
However, by the time cirrhosis becomes clinically apparent, hepatic functional reserve is markedly impaired.
If liver injury cannot be arrested, the prognosis without intervention is poor
-
The onset of complications
(eg, ascites, encephalopathy, variceal hemorrhage) indicates a more advanced stage of disease and a poorer prognosis, with median survival of about 5 years or less.
-
CIRRHOSIS & PORTAL HYPERTENSION
-
CIRRHOSIS Term was 1st coined by Laennec in 1826
Many definitions but common theme is injury, repair, regeneration and scarring
NOT a localized process; involves entire liver
Primary histologic features:1. Marked fibrosis2. Destruction of vascular & biliary elements3. Regeneration4. Nodule formation
-
CIRRHOSIS: PATHOPHYSIOLOGY
Primary event is injury to hepatocellular elements
Initiates inflammatory response with cytokine release->toxic substances
Destruction of hepatocytes, bile duct cells, vascular endothelial cells
Repair thru cellular proliferation and regeneration
Formation of fibrous scar
-
CIRRHOSIS: PATHOPHYSIOLOGY
Primary cell responsible for fibrosis is stellate cell
Become activated in response to injury and lead to ed expression of fibril-forming collagen
Above process is influenced by Kupffer cells which activate stellate cells by eliciting production of cytokines
Sinusoidal fenestrations are obliterated because of ed collagen and EC matrix synthesis
-
CIRRHOSIS: PATHOPHYSIOLOGY
Prevents normal flow of nutrients to hepatocytes and increases vascular resistance
Initially, fibrosis may be reversible if inciting events are removed
With sustained injury, process of fibrosis becomes irreversible and leads to cirrhosis
-
CAUSES OF CIRRHOSIS
Alcohol
Viral hepatitis
Biliary obstruction
Veno-occlusive disease
Hemochromatosis
Wilsons disease
Autommune
Drugs and toxins
Metabolic diseases
Idiopathic
-
CLASSIFICATION OF CIRRHOSIS
WHO divided cirrhosis into 3 categories based on morphological characteristics of the hepatic nodules
1. Micronodular
2. Macronodular
3. Mixed
-
MICRONODULAR CIRRHOSIS
Nodules are
-
MACRONODULAR & MIXED CIRRHOSIS
Nodules are >3 mm in diameter and vary considerably in size
Usually contain portal tracts and efferent veins
Liver is usually normal or reduced in size
Mixed pattern if both type of nodules are present in equal proportions
-
CIRRHOSIS - ALCOHOL
Also known as Laennecs cirrhosis
>50% of pts. with alcoholic cirrhosis die within 4 yrs of diagnosis
Develops in only 10% to 30% of heavy drinkers
Morphologically, micronodular pattern
Multifactorial - genetic, nutritional, drug use and viral
-
CIRRHOSIS - ALCOHOL
Fatty liver, alcoholic hepatitis
Histology - megamitochondria, Mallory bodies, inflammation, necrosis, fibrosis
Key mediator is acetaldehyde (ADH), the product of alcohol metabolism by alcohol dehydrogenase
ADH directly activates stellate cells, inhibits DNA repair and damage microtubules
-
NAFLD/NASH
Nonalcoholic Fatty Liver Disease and Steatohepatitis
Becoming more common
Infiltration of the liver with fat inflammation
Pathologically similar to alcoholic liver but in absence of alcohol
Associated with obesity, hyperlipidemia, NIDDM,
-
VIRAL HEPATITIS
Most common cause of cirrhosis worldwide (>50% of cases)
Incidence of cirrhosis in Hepatitis B pts. is 1% and 10% in Hepatitis C pts.
Incidence increases to 70-80% in HBV +ve pts. who are superinfected with HDV
-
DIAGNOSIS
Can be asymptomatic for decades
History
Physical findings: Hepatomegaly, jaundice, ascites, spider angioma, splenomegaly, palmar erythema, fetor hepaticus, purpura etc.
Elevated LFTs, thrombocytopenia,
-
DIAGNOSIS
Definitive diagnosis is by biopsy or gross inspection of liver
Noninvasive methods include US, CT scan, MRI
Indirect evidence - esophageal varices seen during endoscopy
-
MANIFESTATIONS OF CIRRHOSIS
Hepatorenal syndrome
Hepatic encephalopathy
Portal hypertension
Water retention
Hematologic
Hepatocellular carcinoma
-
PORTAL HYPERTENSION (PH)
Portal vein pressure above the normal range of 5 to 8 mm Hg
Portal vein - Hepatic vein pressure gradient greater than 5 mm Hg (>12 clinically significant)
Represents an increase of the hydrostatic pressure within the portal vein or its tributaries
-
PATHOPHYSIOLOGY OF PH
Cirrhosis results in scarring (perisinusoidal deposition of collagen)
Scarring narrows and compresses hepatic sinusoids (fibrosis)
Progressive increase in resistance to portal venous blood flow results in PH
Portal vein thrombosis, or hepatic venous obstruction also cause PH by increasing the resistance to portal blood flow
-
PATHOPHYSIOLOGY OF PH
As pressure increases, blood flow decreases and the pressure in the portal system is transmitted to its branches
Results in dilation of venous tributaries
Increased blood flow through collaterals and subsequently increased venous return cause an increase in cardiac output and total blood volume and a decrease in systemic vascular resistance
With progression of disease, blood pressure usually falls
-
PORTAL VEIN COLLATERALS
Coronary vein and short gastric veins -> veins of the lesser curve of the stomach and the esophagus, leading to the formation of varices
Inferior mesenteric vein -> rectal branches which, when distended, form hemorrhoids
Umbilical vein ->epigastric venous system around the umbilicus (caput medusae)
Retroperitoneal collaterals ->gastrointestinal veins through the bare areas of the liver
-
ETIOLOGY OF PH
Causes of PH can be divided into
1. Pre-hepatic
2. Intra-hepatic
3. Post-hepatic
-
PRE-HEPATIC PH
Caused by obstruction to blood flow at the level of portal vein
Examples: congenital atresia, extrinsic compression, schistosomiasis, portal, superior mesenteric, or splenic vein thrombosis
-
POST-HEPATIC
Caused by obstruction to blood flow at the level of hepatic vein
Examples: Budd-Chiari syndrome, chronic heart failure, constrictive pericarditis, vena cava webs
-
BUDD-CHIARI SYNDROME
Caused by hepatic venous obstruction
At the level of the inferior vena cava, the hepatic veins, or the central veins within the liver itself
result of congenital webs (in Africa and Asia), acute or chronic thrombosis (in the West), and malignancy
-
BUDD-CHIARI SYNDROME
Acute symptoms include hepatomegaly, RUQ abdominal pain, nausea, vomiting, ascites
Chronic form present with the sequelae of cirrhosis and portal hypertension, including variceal bleeding, ascites, spontaneous bacterial peritonitis, fatigue, and encephalopathy
Diagnosis is most often made by US evaluation of the liver and its vasculature
Cross-sectional imaging using contrast-enhanced CT or MRI
-
BUDD-CHIARI SYNDROME
Gold standard for the diagnosis has been angiography
Management has traditionally been surgical intervention (surgical decompression with a side-to-side portosystemic shunt)
Minimally invasive treatment using TIPS may be first-line therapy now
Response rates to medical therapy are poor
-
PORTAL VEIN THROMBOSIS
Most common cause in children (fewer than 10% of adult pts.)
Normal liver function and not as susceptible to the development of complications, such as encephalopathy
Diagnosis by sonography, CT and MRI
Often, the initial manifestation of portal vein thrombosis is variceal bleeding in a noncirrhotic patient with normal liver function
-
PORTAL VEIN THROMBOSIS - CAUSES
Umbilical vein infection (the most common cause in children)
Coagulopathies (protein C and antithrombin III deficiency),
Hepatic malignancy, myeloproliferative disorders
Inflammatory bowel disease
pancreatitis
trauma
Most cases in adults are idiopathic
-
PORTAL VEIN THROMBOSIS
Therapeutic options are esophageal variceal ligation and sclerotherapy
Distal splenorenal shunt
Rex shunt in patients whose intrahepatic portal vein is patent (most commonly children)
-
SPLENIC VEIN THROMBOSIS
Most often caused by disorders of the pancreas (acute and chronic pancreatitis, trauma, pancreatic malignancy, and pseudocysts)
Related to the location of the splenic vein
Gastric varices are present in 80% of patients
Occurs in the setting of normal liver function
Readily cured with splenectomy (variceal hemorrhage), although observation for asymptomatic patients is acceptable.
-
COMPLICATIONS OF PH
GI bleeding due to gastric and esophageal varices
Ascites
Hepatic encephalopathy
-
VARICES
Most life threatening complication is bleeding from esophageal varices
Distal 5 cm of esophagus
Usually the portal vein-hepatic vein pressure gradient >12 mm Hg
Bleeding occurs in 25-35% of pts. With varices and risk is highest in 1st yr.
-
PREVENTION OF VARICES
Primary prophylaxis: prevent 1st episode of bleeding
Secondary prophylaxis: prevent recurrent episodes of bleeding
Include control of underlying cause of cirrhosis and pharmacological, surgical interventions to lower portal pressure
-
PREVENTION OF VARICES
Beta blockade: Beta blockade (Nadolol, Propranolol)
Nitrates:Organic nitrates
Surgery: No longer performed*
Endoscopy: Sclerotherapy (no longer used*) and variceal ligation
* Refers to primary prophylaxis
-
TREATMENT OF VARICES
Initial Management:
1. Airway control
2. Hemodynamic monitoring
3. Placement of large bore IV lines
4. Full lab investigation (Hct, Coags, LFTs,)
5. Administration of blood products
6. ICU monitoring
-
PHARMACOLOGIC TREATMENT OF VARICES
Decreases the rate of bleeding
Enhances the endoscopic ability to visualize the site of bleeding
Vasopressin - potent splanchnic vasoconstrictor; decreases portal venous blood flow and pressure
Somatostatin: decrease splanchnic blood flow indirectly; fewer side effects
Octreotide: Initial drug of choice for acute variceal bleeding
-
ENDOSCOPIC THERAPY FOR VARICES
Endoscopic Sclerotherapy: complications occur in 10-30% and include fever, retrosternal chest pain, dysphagia, perforation
Endoscopic variceal ligation: becoming the initial intervention of choice; success rates range from 80-100%
-
BALLOON TAMPONADE
Sengstaken-Blakemore tube
Minnesota tube
Alternative therapy for pts. who fail pharmacologic or endoscopic therapy
Complications: aspiration, perforation, necrosis
Limited to 24 hrs; works in 70-80%
-
TIPS
Transjugular inrahepatic portasystemic shunt
1st line treatment for bleeding esophageal varices when earlier-mentioned methods fail
Performed in IR
Success rates 90-100%
Significant complication is hepatic encephalopathy
-
SURGICAL INTERVENTION
Liver transplantation: only definitive procedure for PH caused by cirrhosis
Shunts
Totally diverting (end-side portacaval)
Partially diverting (side-side portacaval)
Selective (distal splenorenal shunt)
Devascularization
-
SEVERE COMPLICATIONS
such as spontaneous bacterial peritonitis or ascites that is refractory to diuretic therapy, occur in the most advanced disease and are associated with a median life expectancy of less than 1 year.
-
Cirrhosis, even if early and stable, predisposes to development of primary hepatocellular carcinoma in as many as 3% of patients per year.
-
Until recently, little could be done to alter the prognosis of patients with cirrhosis and most died of complications. Today, the outlook has begun to change because of advances in orthotopic liver transplantation and development of therapies to prevent and treat complications.
-
BIOLOGIC BASIS OF HEPATIC FIBROSIS
Hepatic fibrosis is a wound-healing response
The same cell type produce hepatic fibrosis regardless of the underling cause.
hepatic fibrosis follows chronic,but not self-limited,injury.
Fibrosis occurs earliest in regions where injury is most severe.
-
ANTIFIBROTIC THERAPIES :RATIONALE AND SPECIFIC AGENT
The paradigm of satellite cell activation provides an important framework to define potential sites of antifibrotic therapy follows
1.Cure the primary disease to prevent injury.
2.Reduce inflammation or the host response to avoid stimulating satellite cells.
3.Directly down regulate stellate cell activation
-
ANTIFIBROTIC THERAPIES :RATIONALE AND SPECIFIC AGENT
4.Neutralize the proliferative,fibrogenic,contractile,and proinflammatory responses of stellate cells.
5.Stimulate apoptosis of stellate cells.
6.Increase the degradation of scar martix,either by stimulating cells that produce matrix proteases,down-regulating their inhibitors ,or directly administering matrix proteases.
-
DIAGNOSTIC APPROACH
Unless the diagnosis is already established, specific serologic tests and often a liver biopsy are required to establish the cause of the cirrhosis .
-
DIAGNOSTIC APPROACH
In addition, patients should undergo laboratory testing to document the severity of the disease and assessment of whether ascites or hepatic encephalopathy is present ..
-
DIAGNOSTIC APPROACH
Obtaining this information helps to determine prognosis, the possibility of specific therapy, and the possible necessity for screening family members for inherited diseases or chronic viral hepatitis
-
SPECIFIC THERAPY MAY BE INDICATED
Antiviral therapy for chronic hepatitis C and B,
Corticosteroids (with or without immunosuppressive therapy) for autoimmune hepatitis,
Phlebotomy for hereditary hemochromatosis,
Penicillamine for Wilson's disease.
-
In some cases, even hepatic fibrosis can be reversed; examples include abstinence from alcohol in alcoholic liver disease and immunosuppressive therapy in autoimmune hepatitis
-
30 - 50 Years
Progression of Hepatitis B Infection
Short-term
Infection
Long-term
HepatitisCirrhosis
Liver
CancerDeath
Long-term
Carrier
Resolution
Cirrhosis
Resolution
Death
Silent
Cirrhosis
-
INITIAL TESTING SHOULD CONSIST OF THE FOLLOWINGMeasurement of serum aminotransferases, bilirubin, alkaline phosphatase, albumin, creatinine, and sodium (otherwise unexplained hyponatremia is a marker of severe disease), the blood urea nitrogen, platelet count, and prothrombin time
.
-
INITIAL TESTING SHOULD CONSIST OF THE FOLLOWING
Abdominal ultrasonography to assess the portal circulation. In one study, the severity of liver disease correlated with portal vein blood velocity as determined by ultrasound
-
Portal hypertension is the most common and lethal complication of chronic liver disease
Esophageal varices and hemorrhage ascites renal dysfunction hypersplenism portal-systemic encephalopathy
P H.. PPG>5mmHg
-
HEPATOCELLULAR CARCINOMA
The issue of periodic surveillance of such patients with serum alpha-fetoprotein (AFP) measurements (values above 20 g/L being abnormal) and ultrasound examinations remains a contentious issue from the viewpoint of cost-effectiveness since an improvement in survival has not yet been demonstrate
-
All patients with cirrhosis should be evaluated for the presence of varices because of the beneficial effect of prophylaxis with propranolol or nadolol
-
Patients with most forms of cirrhosis, particularly due to hepatitis B and C, hereditary hemochromatosis, and alcoholic liver disease, are at high risk (1 to 6 percent per year) for the development of hepatocellular carcinoma
-
A.CURE THE PRIMARY DISEASE
Clear chronic viral infection
Abstinence from alcohol,stop toxic drugs
Remove iron ,copper in overload disease
Eradicate schistosomiasis
Reverse biliary obstruction
Revers jejunoileal bypass
-
NONALCOHOLIC STEATOHEPATITIS NASH
NASH is a disorder diagnosed by liver biopsy. The biopsy findings are indistinguishable from those of alcoholic hepatitis described above but the patient lacks a history of significant alcohol consumption. The liver disease is stable in most patients but a minority progress to cirrhosis
-
CIRRHOSIS & PORTAL HYPERTENSION
SURGICAL COMPLICATIONS
Turner Lisle
Resident Teaching Conference
May 2008
-
CIRRHOSIS
End result of anything that causes hepatocellular
injury
Toxins, viruses, prolonged cholestasis, autoimmunity, metabolic disorders
Pathologic response is uniform
Hepatocellular necrosis
Fibrosis
Nodular regeneration
-
CIRRHOSIS - WHY DO WE CARE
Hepatic failure
Portal hypertension - variceal bleeding
Ischemia & autoimmune factors thought
to play a role, although mechanism is not
clear
-
ANATOMY
Dual blood supplyHepatic arterial Portal venous
Total hepatic blood flow ~1500 mL/min or 25% of cardiac output
Portal vein 2/3 of total hepatic blood flow
Hepatic artery>1/2 of O2
-
PORTAL HYPERTENSION
Usually due to increased portal venous resistance
Classification based on site of increased resistance
Prehepatic
Intrahepatic
-
PREHEPATIC PORTAL HTN
Portal vein thrombosis most common
Isolated splenic vein thrombosis
Usually caused by pancreatic inflammation or neoplasm
Results in gastrosplenic HTN with ensuing formation of gastric varices
Normal superior mesenteric & portal vein pressure
Easily reversed by splenectomy alone
-
INTRAHEPATIC PORTAL HTN
Often a combination of pre-, intra-, or post-sinusoidal
Presinusoidal Schistosomiasis Nonalcoholic cirrhosis
Sinusoidal EtOH
Postsinusoidal - overall rare EtOH Budd-Chiari syndrome (hepatic vein thrombosis) Constrictive pericarditis Heart failure
-
PORTAL HYPERTENSION
Portal pressure > 5 mmHg
Portal pressure > 8 mmHg needed for collateralization
-
COLLATERALIZATION
-
EVALUATION OF THE CIRRHOTIC
1) Dx of underlying liver disease
2) Estimation of fxn hepatic reserve
3) Definition of portal venous anatomy
4) Hepatic hemodynamic evaluation
5) If present, identification of site of UGI bleeding
-
EVALUATION OF THE CIRRHOTIC
Physical Exam
Jaundice
Ascites
Caput medusae
Asterixis
Spider angiomas
Palmer erythema
Testicular atrophy
Gynecomastia
+/- Palpable spleen (portal HTN)
Lab tests
Anemia
Thrombocytopenia
Coagulopathy
Hypoalbuminemia
AST/ALT
Bili
Alk Phos
GGT
Hepatitis serologies
-fetoprotein
-
LIVER BIOPSY
Cause of cirrhosis
Activity of liver disease
Approaches
Percutaneous (avoid with ascites or INR)
Transjugular venous
Laparoscopic
Open
-
HEPATIC FUNCTIONAL RESERVE
CHILD-PUGH Encephalopathy grade Amount of ascites Bilirubin Albumin PT (INR)
Operative mortality A (5%) B (10-15%) C (25%)
Subjective
MELD Bilirubin INR Creatinine Cr Max = 4.0 mg/dL On dialysis calculate with CR = 4.0 mg/dL
Calculators on the web
-
MELD 5-20
1% increase in mortality with each integer rise in
MELD score
MELD >20
Additional 2% increase in mortality with each integer
rise in MELD score
-
DIAGNOSIS OF BLEEDING
NGT decompression & lavage
Endoscopy - key procedure for UGIB
UGIB with portal HTN
90% due to varices
10% other causes (Mallory-Weiss tears, ulcers, etc)
Majority are esophagogastric varices
Isolated gastric varices
Likely splenic vein thrombosis
-
VARICEAL HEMMORRHAGE
Single most life threatening complication of portal HTN
Risk of death is related to the underlying hepatic functional reserve
Pathogenesis of rupture incompletely understood
Multifactorial
Portal pressure >12mmHg
Treatment
Control the bleeding
Control the portal HTN
-
TREATMENT OF ACUTE VARICEAL BLEEDING
Emergency tx should be non-operative
Resuscitation first
Endoscopy Successful in >85%
Pharmacotherapy Vasopressin +/- NTG Somatostatin/Octreotide (fewer complications)
Balloon tamponade (rare)
TIPS
-
ENDOSCOPIC TREATMENT
Most common treatment modality for acute bleeding as well as prevention
Sclerosis
Ligation
Complications Esophageal ulceration Perforation Worsening hemorrhage Aspiration
Failure after two unsuccessful attempts
Equally efficacious (80-90%)
-
Potentially lethal complications
as pharmacotherapy and endoscopy
Has been shown to be as effective
-esophageal perforation-ischemic necrosis of esophagus
May be life saving
Deflation followed by
high re-bleeding rate
Sengstaken-Blakemore tube
-
TIPS
Portal decompression without surgery (nonselective shunt)
Not recommended as initial therapy for acute variceal bleeding
Preferred tx when pharmacotherapy and endoscopic means have failed
Best when used as a bridge to transplant
Problems include shunt stenosis/occlusion, encephalopathy (50% at 1-year)
Transjugular Intrahepatic Portosystemic Shunt
-
EMERGENCY SURGERY
Indications
Failure of acute endoscopic tx
Failure of TIPS placement
Hemorrhage from gastric varices
Esophageal transection rapid/simple
Portacaval shunt or splenorenal shunt
Operative mortality >25% in most series
-
PREVENTION OF RECURRENT HEMORRHAGE
Likelihood of repeat episodes >70%
Goals Prevention of recurrent bleeding Maintenance of satisfactory hepatic function
Options Pharmacotherapy (-blockers +/- nitrates) Chronic endoscopy (successful in 2/3) TIPS (less bleeding, more encephalopathy) Operative shunts Transplantation
-
PORTOSYSTEMIC SHUNTS
Most effective means of preventing recurrent bleeding in patients with portal hypertension
Problems
Encephalopathy
Accelerated hepatic failure
Types
Nonselective - End-to-end/side portocaval
Selective - Distal splenorenal
Partial - Small diameter PTFE
-
NONSHUNT PROCEDURES
ObjectivesAblation of varices Extensive interruption of collateral vessels
Options Transection and reanastamosis of the distal esophagus Extensive esophagogastric devascularization + esophageal transection and splenectomy
Rebleeding rates similar to endoscopic
experience
-
ASCITES
Usually an indicator of advanced cirrhosis
Initiated by altered hepatic and splanchnic hemodynamics
Intravascular volume deficit resulting in increased aldosterone..
Central goal is to achieve a NEGATIVE sodium balance
-
ASCITES TREATMENT
Dietary restriction
Dietary restriction + Diuretics spironolactone +/- lasix
5-10% are refractory Intermittent paracentesis TIPS Peritoneovenous Denver shunt (rarely used)
SBP PMN >250/mm3 or positive culture
-
ENCEPHALOPATHY
Variety of manifestations
Pathogenesis - circulating cerebral toxins Ammonia
Mercaptans -aminobutyric acid
Precipitated by multiple factors Shunts, hemorrhage, excessive diuresis, azotemia, infection, increased
dietary protein, sedatives
Management Eliminate/treat precipitating factors Lactulose, neomycin (decrease absorption of intestinal ammonia)
-
May you success in any path you have chosen.